(JT Med Genet 1993; 30:807-12) Congenital heart disease (CHD) occurs in approximately 8 in 1000 livebirths and is one of the most common major congenital anomalies. ' The majority of congenital heart defects occur as isolated malformations. Studies to elucidate an aetiology have proven to be difficult. Epidemiological studies have indicated a variable but increased risk of recurrence in families with one affected proband and a higher recurrence risk if the mother is affected.2" This suggests a genetic predisposition to cardiac malformation which may be influenced by in utero environment or genetic background. However, the genetic contribution remains to be defined.
Congenital cardiac defects are frequently observed in association with other malformations and as a feature of well defined genetic syndromes. In some syndromes, specific types of CHD are overrepresented as compared to their incidence in the general population. For example, over 40% of patients with Down's syndrome (trisomy 21) have CHD; approximately 40% of those with CHD will have a complete common atrioventricular canal, which is an otherwise uncommon lesion in the non-syndromic patient.' However, a narrowly defined chromosomal region has not been linked to the development of this particular type of CHD.
Conotruncal cardiac defects are one feature of DiGeorge syndrome (DGS) where they are seen in association with thymic and parathyroid gland hypoplasia or aplasia.67 The types of conotruncal defects, particularly interrupted aortic arch type B (IAA), truncus arteriosus (TA), and tetralogy of Fallot (TOF), are overrepresented in this subgroup of patients as compared to their incidence in the general population.8 TOF is also one of the most common cardiac defects seen in velocardiofacial syndrome (VCFS), which is characterised by CHD, palatal abnormalities, learning disabilities, and a characteristic facies.'2 Clinical overlap between DGS and VCFS has been suggested by several investigators since features of DGS, such as hypocalcaemia and immunodeficiencies, have been reported in patients with VCFS.1314 Recent molecular studies have shown microdeletions of chromosome 22, within 22ql 1, in the majority of patients with DGS and VCFS, and in some familial cases of congenital heart disease. 152' This deleted region, the DiGeorge critical region (DGCR), presumably encodes for genes necessary for normal development of the derivatives of the third and fourth pharyngeal pouches: the thymus, parathyroid glands, and conotruncus. Based on these findings, we hypothesised that non-syndromic patients with conotrunal cardiac defects might also have deletions within the DGCR or in a partially overlapping region. To test this hypothesis, we have evaluated 17 patients with conotruncal cardiac malformations for microdeletions of 22ql 1 using restriction fragment length polymorphism (RFLP) and dosage analysis. 
